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Poster Session-I 83targeted therapies are thus needed to improve outcomes and immu-
notherapy has the potentials to fulfill this need. We have previously
shown that genetically modified T cells expressing a chimeric anti-
gen receptor (CAR) composed of NKG2D and the CD3-z chain
have potent antitumor activity against several adult malignancies.
Since at present only limited targets are available for the immuno-
therapy of osteosarcoma, the aim of this study was to determine if
NKG2D-ligands (NKG2D-L) are expressed on the cell surface of
osteosarcoma and if NKG2D-L-specific T cells recognize and kill
osteosarcoma.
Methods and Results:NKG2D-L expression was determined by
FACS analysis as well as RT-PCR. 7 out of 8 cell lines tested
expressed one or several NKG2D-L on their cell surface.
NKG2D-L-specific T cells were generated by transducing CD3/
CD28-activated T cells with a SFG retroviral vector encoding the
NKG2D-L-specific CAR and truncated CD19 to allow detection
of transduced T cells. NKG2D-L-specific T cells from healthy
donors produced IFN-g in contrast to mock transduced T cells after
coculture withNKG2D-L-positive osteosarcoma cells. In cytotoxic-
ity assays, NKG2D-L-specific T cells killed NKG2D-L-positive
osteosarcoma cells where as activated, autologous lymphocytes and
NKG2D-L-negatvie osteosarcoma cells were not killed.
Conclusion:We have shown that NKG2D ligands are expressed
on osteosarcoma and that NKG2D-L specific T cells recognize and
kill osteosarcoma. Murine xenograft studies are in progress to con-
firm these findings in vivo. Adoptive immunotherapy with
NKG2D-L-specific T cells may represent a promising immunother-
apeutic approach for osteosarcoma.SOLID TUMORS
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CCR2B-TRANSDUCED CYTOTOXIC T LYMPHOCYTES SHOW ENHANCED
HOMING IN VIVO TOWARD CCL2-SECRETING NEUROBLASTOMA:
IMPLICATIONS FOR ENHANCED ADOPTIVE IMMUNOTHERAPY
Craddock, J.A., Lu, A., Rooney, C.M., Foster, A.E. Baylor College of
Medicine, Houston, TX
The chemokine CCL2 (MCP-1) is produced by a variety of can-
cers including neuroblastoma, melanoma, breast cancer and hemato-
logical malignancies. However, cytotoxic T lymphocytes (CTL)
used in clinical trials to treat these diseases do not express CCR2,
the receptor for CCL2. This deficiency may contribute to subopti-
mal trafficking to tumor sites and reduced clinical efficacy. There-
fore, we examined whether genetically modifying CTL with CCR2
could increase their homing towards tumor cells that produced
CCL2. CTL were first examined by flow cytometry for chemokine
receptor expression using antibodies to CCR2, CCR4, CCR5,
CCR7 and CXCR4. These CTL showed nominal expression
of CCR2 (\1%), low expression of CCR4 (10%), CXCR4 (25%),
CCR7 (5%), and high expression of CCR5 (70%). ELISA for
CCL2 was performed on established neuroblastoma cell lines
(IMR-32, LAN-1, SK-N-SH, JF) and on neuroblastoma cell lines
derived from patients primary tumors. All neuroblastoma cell lines
secreted CCL2 in variation but notably, all patient-derived primary
tumor cell lines secreted high levels of CCL2. T cells were activated
by anti-CD3/anti-CD28 antibody stimulation for 3 days in the pres-
ence of IL-2, and then transduced using a CCR2b retroviral vector.
Expression of CCR2b was detected by flow cytometry producing up
to 78% transduction. In vitro chemotaxis of CCR2b-transduced T
cells showed enhance migration to soluble CCL2 (.3 fold) as well
as to supernatants from CCL2-secreting cell lines (.2 fold) com-
pared to non-transduced T cells. To study in vivo migration, we
co-transducedT cells with EGFPluciferase andCCR2b. Subsequent
tail vein infusion of these co-transduced T cells into mice bearing
CCL2 secreting tumors (SK-N-SH) showed preferential migration
of only CCR2b-transduced T cells toward the tumor site when com-
pared to non-transduced T cells. These results demonstrate the fea-
sibility of influencing the trafficking of adoptively transferred T cells
toward CCL2 secreting neuroblastoma and thereby suggesting a po-
tential means to enhance future adoptive immunotherapies targeting
neuroblastoma.228
HIGH DOSE CHEMOTHERAPY WITH BLOOD OR MARROW TRANSPLANT
FOR RHABDOMYOSARCOMA: A CIBMTR ANALYSIS
Stiff, P., Agovi, M.-A., Antman, K., Camitta, B., Cairo, M., Childs, R.,
Edwards, J.R., Gale, R.P., Hale, G., Horowitz, M.M., Lazarus, H.,
Arora, M. CIBMTR, Milwaukee, WI
Rhabdomyosarcoma, the commonest soft tissue sarcoma in chil-
dren is initially chemosensitive with cures in 70%, but 5 year survival
for relapsed patients is 15–20% and only 5% for those with alveolar/
undifferentiated subtypes. Since autologous stem cell transplanta-
tion (ASCT) is not clearly defined for this disease, we describe out-
comes of 62 patients who received ASCT from 1989–2003 and
reported to CIBMTR. Pathology was confirmed through review of
reports for all cases. Transplant related mortality (TRM), progres-
sion-free survival (PFS) and overall survival (OS) were evaluated.
We also compared subgroups: poor risk histology (alveolar/undiffer-
entiated, n5 34) vs good risk (embryonal/botryoid, n5 21); patients
in 1st remission (REM1, n5 38) vs patients who relapsed (REL, n5
21); those presenting with metastases (n5 39) vs those without (n5
19); patients with poor risk histology who were in REM1 (n5 20) vs
REL (n5 12) and those with good risk histology who were in REM1
(n5 13) vs REL (n5 8). For the entire cohort, 73%were\20 yrs in
age, 52% were male, 39% presented with bulk .5cm, and 63% had
metastasis at diagnosis. Fifty percent had alveolar histology, 32%
embryonal subtype, 67% were in REM1, and 92% were chemosen-
sitive at ASCT. The conditioning regimens included melphalan in
53% and etoposide in 67%. There were no differences in the remis-
sion status at ASCT (63% vs 62% in REM1; p5 0.9) or median time
from diagnosis to ASCT (p 5 0.7) for those with good vs poor risk
histology. Patients with poor risk histology were more likely to
have marrow involved at diagnosis (44 vs 14%;p5 0.2), a CR to pri-
mary therapy (53% vs 26%;p 5 0.1) and being in a CR at ASCT
(70% vs 48%;p 5 0.2). For the entire group, the TRM at 1 year
was 5% (95% CI, 1–12); the 5 year PFS and OS were 29% (95%
CI, 18–41) and 32%(95% CI, 21–44) respectively. There were no
significant difference in 5 year PFS and OS between: those with
poor risk vs good risk histology (p5 0.6;p5 0.9), those transplanted
in REM1 vs REL (36% vs 29%;p5 0.5), those with poor risk histol-
ogy transplanted in REM1 vs REL (34% vs 33%;p 5 0.9), or those
with good risk histology transplanted in REM1 vs REL (38% vs
25%;p 5 0.2). These data indicate that ASCT for this disease are
typically done for patients with chemosensitive disease and suggest
that when performed after relapse, long-term survival is seen in ap-
proximately 1/3, seemingly better than previous reports of standard
dose salvage for those with alveolar/undifferentiated histologies.229
DEPLETION OF CD4 T CELLS LEADS TO INCREASED TUMOR IMMUNITY
AFTER HSCT IMMUNOTHERAPY BUT RESULTS IN LOSS OF MEMORY
Jing, W., Johnson, B.D. Medical College of Wisconsin, Milwaukee, WI
High-risk neuroblastoma is a clinically challenging disease. We
have demonstrated that established neuroblastoma can be eliminated
in a murine model by using a multi-faceted immunotherapeutic ap-
proach involving syngeneic hematopoietic stem cell transplantation
(HSCT), T cell transfer (cellular immunotherapy), and tumor vacci-
nation. One surprising finding in these experiments was that while
depletion of CD4T cells resulted in decreased anti-tumor immunity
in mice given naı¨ve T cells as cellular immunotherapy, if the trans-
ferred T cells were pre-sensitized to tumor antigens (i.e., from
tumor-vaccinated donors) CD4 depletion resulted in increased
anti-tumor immunity. The increased anti-tumor efficacy in these
CD4-depleted hosts was accompanied by: (a) more vigorous prolif-
eration of CD8 cells in the spleens and tumor-draining lymph nodes
as observed in CFSE-labeling studies, (b) elevated percentages of
CD8T cells with a CD62L-CD441 effector phenotype, (c) elevated
frequencies and absolute numbers of splenic tumor-reactive (IFN-g-
producing) CD8 cells, and (d) more robust tumor infiltration by
CD8 cells. However, development of long-term tumor immunity
(memory) was severely compromised in these CD4-depleted hosts,
as reflected by inability to resist a tumor re-challenge and diminished
in vitro CD8 recall responses. This loss of memory occurred even
though the adoptively transferred CD8 T cells were from donors
that had been vaccinated in the presence of CD4 cells, indicating
